The Role of Progesterone Metabolism and Androgen Synthesis in Renal Blood Pressure Regulation

Abstract

11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) plays a crucial role in converting hormonally active cortisol into inactive cortisone, conferring specificity onto the human mineralocorticoid receptor (MR). Progesterone binds with even higher affinity to the MR, but acts as an MR antagonist. How aldosterone is able to keep its function as predominant MR ligand in clinical situations with high progesterone concentrations, such as pregnancy, is not clear. We have shown in vitro that the human kidney possesses an effective enzyme system that metabolizes progesterone to inactive metabolites in a process similar to the inactivation of cortisol by 11β-HSD2. In studies on patients with adrenal insufficiency, we have shown that the in vivo anti-mineralocorticoid activity of progesterone is diminished by inactivating metabolism of progesterone, local formation of the deoxycorticosterone mineralocorticoid from progesterone, and inhibition of 11β-HSD2 by progesterone and its metabolites resulting in decreased inactivation of cortisol and hence increased MR binding by cortisol. The enzymes involved in progesterone metabolism are also responsible for the capability of the human kidney to convert pregnenolone to DHEA and androstenedione leading to the formation of active androgens, testosterone and 5α-DH-testosterone. Locally produced androgens might be responsible for the observed difference in blood pressure between men and women and higher susceptibility to hypertension in men.

Key words

Progesterone - Androgens - Human kidney - Hypertension

References

• 1 Stockand J D. New ideas about aldosterone signaling in epithelia.  Am J Physiol Renal Physiol. 2002;  282 F559-F576
• 2 Arriza J L, Weinberger C, Cerelli G, Glaser T M, Handelin B L, Housman D E, Evans R M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.  Science. 1987;  237 268-275
• 3 Funder J W, Pearce P T, Smith R, Smith A I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated.  Science. 1988;  242 583-585
• 4 Edwards C R, Stewart P M, Burt D, Brett L, McIntyre M A, Sutanto W S, de Kloet E R, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor.  Lancet. 1988;  2 986-989
• 5 Quinkler M, Oelkers W, Diederich S. Clinical implications of glucocorticoid metabolism by 11beta-hydroxysteroid dehydrogenases in target tissues.  Eur J Endocrinol. 2001;  144 87-97
• 6 Walker E A, Stewart P M. 11beta-hydroxysteroid dehydrogenase: unexpected connections.  Trends Endocrinol Metab. 2003;  14 334-339
• 7 New M I, Levine L S, Biglieri E G, Pareira J, Ulick S. Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension.  J Clin Endocrinol Metab. 1977;  44 924-933
• 8 Werder E, Zachmann M, Vollmin J A, Veyrat R, Prader A. Unusual steroid excretion in a child with low renin hypertension.  Research in steroids. 1974;  6 385-389
• 9 Stewart P M, Corrie J E, Shackleton C H, Edwards C R. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.  J Clin Invest. 1988;  82 340-349
• 10 Stewart P M, Krozowski Z. 11beta-hydroxysteroid dehydrogenase.  Vitamins and Hormones. 1999;  57 249-324
• 11 Quinkler M, Stewart P M. Hypertension and the cortisol-cortisone shuttle.  J Clin Endocrinol Metab. 2003;  88 2384-2392
• 12 Oelkers W K. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure.  Steroids. 1996;  61 166-171
• 13 Murakami T, Watanabe Ogura E, Tanaka Y, Yamamoto M. High blood pressure lowered by pregnancy.  Lancet. 2000;  356 1980
• 14 Rupprecht R, Reul J M, van Steensel B, Spengler D, Soder M, Berning B, Holsboer F, Damm K. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands.  Eur J Pharmacol. 1993;  247 145-154
• 15 Souque A, Fagart J, Couette B, Davioud E, Sobrio F, Marquet A, Rafestin Oblin ME. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent.  Endocrinology. 1995;  136 5651-5658
• 16 Johansson E D, Jonasson L E. Progesterone levels in amniotic fluid and plasma from women. I. Levels during normal pregnancy.  Acta Obstet Gynecol Scand. 1971;  50 339-343
• 17 Rosenthal H E, Slaunwhite W R , Sandberg A A. Transcortin: a corticosteroid-binding protein of plasma. X. Cortisol and progesterone interplay and unbound levels of these steroids in pregnancy.  J Clin Endocrinol Metab. 1969;  29 352-367
• 18 Nolten W E, Lindheimer M D, Oparil S, Ehrlich E N. Desoxycorticosterone in normal pregnancy. I. Sequential studies of the secretory patterns of desoxycorticosterone, aldosterone, and cortisol.  Am J Obstet Gynecol. 1978;  132 414-420
• 19 Quinkler M, Johanssen S, Grossmann C, Bähr V, Müller M, Oelkers W, Diederich S. Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites.  J Clin Endocr Metabol. 1999;  84 4165-4171
• 20 Quinkler M, Johanssen S, Bumke-Vogt C, Oelkers W, Bahr V, Diederich S. Enzyme-mediated protection of the mineralocorticoid receptor against progesterone in the human kidney.  Mol Cell Endocrinol. 2001;  171 21-24
• 21 Quinkler M, Meyer B, Bumke-Vogt C, Grossmann C, Gruber U, Oelkers W, Diederich S, Bahr V. Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor.  Eur J Endocrinol. 2002;  146 789-799
• 22 Laidlaw J C, Ruse J L, Gornall A G. The influence of estrogen and progesterone on aldosterone excretion.  J Clin Endocr Metabol. 1962;  22 161-171
• 23 Landau R L, Bergenstal D M, Lugibihl K, Kascht M E. The metabolic effects of progesterone in man.  J Clin Endocrinol Metab. 1955;  15 1194-1215
• 24 Landau R L, Lugibihl K, Bergenstal D M, Dimick D F. The metabolic effects of progesterone in man: Dose response relationships.  J Lab Clin Med. 1957;  50 613-620
• 25 Landau R L, Lugibihl K. Inhibition of the sodium-retaining influence of aldosterone by progesterone.  J Clin Endocrinol Metab. 1958;  18 1237-1245
• 26 Oparil S, Ehrlich E N, Lindheimer M D. Effect of progesterone on renal sodium handling in man: relation to aldosterone excretion and plasma renin activity.  Clin Sci Mol Med. 1975;  49 139-147
• 27 Oelkers W, Schöneshöfer M, Blümel A. Effects of progesterone and four synthetic progestagens on sodium balance and the renin-aldosterone system in man.  J Clin Endocrinol Metab. 1974;  39 882-890
• 28 Quinkler M, Meyer B, Oelkers W, Diederich S. Renal inactivation, mineralocorticoid generation, and 11beta-hydroxysteroid dehydrogenase inhibition ameliorate the antimineralocorticoid effect of progesterone in vivo.  J Clin Endocrinol Metab. 2003;  88 3767-3772
• 29 Burt V L, Whelton P, Roccella E J, Brown C, Cutler J A, Higgins M, Horan M J, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988 - 1991.  Hypertension. 1995;  25 305-313
• 30 Stamler R, Stamler J, Riedlinger W F, Algera G, Roberts R H. Weight and blood pressure. Findings in hypertension screening of 1 million Americans.  JAMA. 1978;  240 1607-1610
• 31 Bachmann J, Feldmer M, Ganten U, Stock G, Ganten D. Sexual dimorphism of blood pressure: possible role of the renin-angiotensin system.  J Steroid Biochem Mol Biol. 1991;  40 511-515
• 32 Harshfield G A, Alpert B S, Pulliam D A, Somes G W, Wilson D K. Ambulatory blood pressure recordings in children and adolescents.  Pediatrics. 1994;  94 180-184
• 33 August P. Hypertension in men.  J Clin Endocrinol Metab. 1999;  84 3451-3454
• 34 Reckelhoff J F, Zhang H, Srivastava K, Granger J P. Gender differences in hypertension in spontaneously hypertensive rats: role of androgens and androgen receptor.  Hypertension. 1999;  34 920-923
• 35 Reckelhoff J F, Granger J P. Role of androgens in mediating hypertension and renal injury.  Clin Exp Pharmacol Physiol. 1999;  26 127-131
• 36 Ding Y, Sigmund C D. Androgen-dependent regulation of human angiotensinogen expression in KAP-hAGT transgenic mice.  Am J Physiol Renal Physiol. 2001;  280 F54-60
• 37 Wilson C M, McPhaul M J. A and B forms of the androgen receptor are expressed in a variety of human tissues.  Mol Cell Endocrinol. 1996;  120 51-57
• 38 Pelletier G. Localization of androgen and estrogen receptors in rat and primate tissues.  Histol Histopathol. 2000;  15 1261-1270
• 39 Reckelhoff J F, Zhang H, Granger J P. Testosterone exacerbates hypertension and reduces pressure- natriuresis in male spontaneously hypertensive rats.  Hypertension. 1998;  31 435-439
• 40 Brignardello E, Gallo M, Aragno M, Manti R, Tamagno E, Danni O, Boccuzzi G. Dehydroepiandrosterone prevents lipid peroxidation and cell growth inhibition induced by high glucose concentration in cultured rat mesangial cells.  J Endocrinol. 2000;  166 401-406
• 41 Quinkler M, Bumke-Vogt C, Meyer B, Bahr V, Oelkers W, Diederich S. The human kidney is a progesterone-metabolizing and androgen-producing organ.  J Clin Endocrinol Metab. 2003;  88 2803-2809
• 42 Bumke-Vogt C, Bahr V, Diederich S, Herrmann S M, Anagnostopoulos I, Oelkers W, Quinkler M. Expression of the progesterone receptor and progesterone-metabolising enzymes in the female and male human kidney.  J Endocrinol. 2002;  175 349-364
• 43 Dunn J F, Nisula B C, Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma.  J Clin Endocrinol Metab. 1981;  53 58-68
• 44 Winkel C A, Simpson E R, Milewich L, MacDonald P C. Deoxycorticosterone biosynthesis in human kidney: potential for formation of a potent mineralocorticosteroid in its site of action.  Proc Natl Acad Sci U S A. 1980;  77 7069-7073